Drug intelligence / Profile preview

DICE

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

DICE is a combination chemotherapy regimen composed of Dexamethasone, Ifosfamide, Cisplatin, and Etoposide. This regimen is utilized in the treatment of various hematological malignancies, including NK/T cell lymphoma and relapsed or refractory B-cell Non-Hodgkin's Lymphoma. It has been investigated both as a foundational chemotherapy and in conjunction with other therapeutic agents.

Other names: Dexamethasone Ifosfamide Cisplatin Etoposide

Targets

TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on DICE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DICE.

Explore the full profile